InSilicoTrials utilizes computational modeling and artificial intelligence to streamline drug and medical device development, significantly reducing the time and costs associated with R&D. By minimizing reliance on animal testing and clinical trials, the platform enhances product safety while accelerating the path to market.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of new drugs and medical devices is a lengthy and expensive process, often requiring extensive animal testing and clinical trials. These traditional methods can delay the availability of new treatments and increase R&D costs.
Solution
InSilicoTrials offers a cloud-based platform that leverages computational modeling and AI to accelerate the R&D process for drugs and medical devices. The platform provides access to a library of validated computational models developed by scientists from universities and research centers. These models enable pharmaceutical companies to simulate drug behavior and device performance, reducing the need for animal testing and clinical trials. By using the platform, researchers can identify promising candidates earlier in the development cycle, optimize dosages, and assess safety profiles, leading to faster time-to-market and reduced costs.
Target Audience
The primary customers are pharmaceutical companies, medical device manufacturers, and research institutions seeking to accelerate their R&D process, reduce costs, and improve the safety of their products.
Features
- Cloud-based platform accessible from anywhere in the world with total data security
- Library of validated computational models for simulating drug behavior and device performance
- AI-driven tools for identifying promising candidates and optimizing dosages
- Support for regulatory certification by bodies such as FDA and EMA
- Simplified user interface for researchers without expertise in digital simulation
- Pay-per-use model, reducing the costs associated with software, IT infrastructure, and specialized personnel
- Drug Safety Suite to reduce the risk of cardiotoxicity from drugs
- Virtual screening of different concentrations to identify the correct dosage of new pharmacological compounds